Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The clinical progress of mRNA vaccines and immunotherapies
Ann Barbier, Allen Yujie Jiang, Peng Zhang, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 6, pp. 840-854
Open Access | Times Cited: 468

Showing 1-25 of 468 citing articles:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 405
The landscape of mRNA nanomedicine
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 305
Unlocking the promise of mRNA therapeutics
Eduarde Rohner, Ran Yang, Kylie S. Foo, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 11, pp. 1586-1600
Open Access | Times Cited: 289
mRNA-based cancer therapeutics
Chuang LIU, Qiangqiang Shi, Xiangang Huang, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 8, pp. 526-543
Closed Access | Times Cited: 201
A Comprehensive Review of mRNA Vaccines
Vrinda Gote, Pradeep Kumar Bolla, Nagavendra Kommineni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2700-2700
Open Access | Times Cited: 180
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Yan Zong, Yi Lin, Tuo Wei, et al.
Advanced Materials (2023) Vol. 35, Iss. 51
Closed Access | Times Cited: 161
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Edo Kon, Nitay Ad‐El, Inbal Hazan‐Halevy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 739-754
Open Access | Times Cited: 127
Engineering cytokine therapeutics
Jeroen Deckers, Tom Anbergen, Ayla M. Hokke, et al.
Nature Reviews Bioengineering (2023) Vol. 1, Iss. 4, pp. 286-303
Open Access | Times Cited: 114
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
Erik Oude Blenke, Eivor Örnskov, Christian Schöneich, et al.
Journal of Pharmaceutical Sciences (2022) Vol. 112, Iss. 2, pp. 386-403
Open Access | Times Cited: 101
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches
Nazeer Hasan, Arif Nadaf, Mohammad Imran, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 86
Nanotechnology-based mRNA vaccines
Shuying Chen, Xiangang Huang, Yonger Xue, et al.
Nature Reviews Methods Primers (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 70
Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA
Bowen Li, Allen Yujie Jiang, Idris Raji, et al.
Nature Biomedical Engineering (2023)
Closed Access | Times Cited: 68
Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery
Grayson Tilstra, Julien Couture‐Senécal, Yan Ming Anson Lau, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 4, pp. 2294-2304
Closed Access | Times Cited: 67
PEGylated therapeutics in the clinic
Yongsheng Gao, Maithili Joshi, Zongmin Zhao, et al.
Bioengineering & Translational Medicine (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 67
mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications
Yu‐Shiuan Wang, Monika Kumari, Guanhong Chen, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 65
Amplifying gene expression with RNA-targeted therapeutics
Olga Khorkova, Jack Stahl, Aswathy Joji, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 539-561
Open Access | Times Cited: 64
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell
Lu Diao, Mi Liu
Advanced Science (2023) Vol. 10, Iss. 22
Open Access | Times Cited: 60
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines
K. Swetha, Niranjan G. Kotla, Lakshmi Tunki, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 658-658
Open Access | Times Cited: 58
mRNA vaccine in cancer therapy: Current advance and future outlook
Youhuai Li, Mina Wang, Xueqiang Peng, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 8
Open Access | Times Cited: 57
Recent Advancement in mRNA Vaccine Development and Applications
Nojoud AL Fayez, Majed S. Nassar, Abdullah A. Alshehri, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1972-1972
Open Access | Times Cited: 56
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
Bolin Wang, Jinli Pei, Shengnan Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 56
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Hamideh Parhiz, Elena N. Atochina‐Vasserman, Drew Weissman
The Lancet (2024) Vol. 403, Iss. 10432, pp. 1192-1204
Closed Access | Times Cited: 56
Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
Jennifer Connors, David Joyner, Nathan Mege, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 53
Strategies to reduce the risks of mRNA drug and vaccine toxicity
Dimitrios Bitounis, Eric Jacquinet, Maximillian A. Rogers, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 281-300
Closed Access | Times Cited: 52
Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines
Xanthippi Topalidou, Alexis M. Kalergis, Georgios Papazisis
Pathogens (2023) Vol. 12, Iss. 10, pp. 1259-1259
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top